The Utah Office of Artificial Intelligence Policy lists a prescription-refill pilot for August AI as approved and signed on October 2, 2026. Its public record says the demonstration period has not started yet, and that “A Utah licensed provider reviews the first 250 refills before they reach the patient, and reviews each of the next 1,000 afterward”.
We did not read the signed agreement itself.
Business Pill · TRUST GROWS WITH THE RECORD
A one-minute explainer of the idea behind this story: earned autonomy. It teaches the concept, not this story’s figures.
The key insight: The Office’s page describes a review that loosens in numbered steps, and its separate evaluators page says a receipt shows a check ran, not that the AI is safe. These are two statements on two pages. This publication does not say that the evaluators or the receipts apply to August AI’s pilot, because the pages do not say so.
The Office’s page says August AI, operated by August Labs, Inc., “offers an AI health companion app”. The pilot lets its system “authorize routine 30, 60, and 90 day refills of maintenance medication a Utah adult is already taking on an established treatment plan”, “from a fixed list of non controlled medications set out in the agreement”. The page adds: “It does not write a new prescription, change a dose, or substitute one medication for another”.
The entry is headed “Approved” and “Prescription refills”, dated “Signed October 2, 2026”, and says “Co-signed with Division of Professional Licensing”. Under “Term” it says: “The demonstration period has not started yet”.
The two review phases that have numbers on the Utah Office of AI Policy’s Authorized Pilots page: the first 250 refills reviewed before they reach the patient and the next 1,000 reviewed afterward. After that the page says providers spot check at least 5 percent of refills in every medication class. This publication found no refill counts in the pages it read.
The Review Ramp
Under “What the company agreed to”, the page describes a review that loosens in steps. It says a Utah licensed provider reviews “the first 250 refills before they reach the patient”, and “each of the next 1,000 afterward”. It says: “Each new phase requires written approval from this office”. Then: “After that, providers spot check at least 5 percent of refills in every medication class”.
Two other conditions limit each refill. The page lists “No more than three AI refills in a row for any medication at the start, after which the patient must see a human provider”. It also lists “Identity verification, and a check of the patient’s pharmacy record to confirm the medication is still current, before any refill”.
The page says: “Any sign of suicidal thinking, a new side effect, a dangerous interaction, or missing lab monitoring stops the refill and sends it to a licensed provider”. It adds: “Pharmacists are told the refill came from AI, adverse events are reported to this office within 24 hours, and patient data is not sold or used for advertising”.
What the State Agreed to Set Aside
Under “Relief granted”, the page says: “The Division of Professional Licensing agreed not to bring an enforcement action for unlicensed or unprofessional conduct, or under the state telehealth requirements, where the AI authorizes a routine refill of an existing prescription under the agreed protocol”. It adds: “The relief runs to the sections named in Schedule A and expressly reaches nothing else August AI offers”.
The page also sets out limits it says apply to every sandbox agreement. It says “A demonstration period runs no longer than 12 months”, and that “The office may also end an agreement at any time and for any reason”. On endorsement it says: “Taking part in our AI sandbox does not mean the State of Utah has approved, endorsed, certified, or vouched for the product”.
On monitoring, the page says “Every AI sandbox participant reports to us monthly for as long as its agreement is in force”, with reports that carry numbers: “how many requests the system handled, how often a reviewing clinician agreed with it, and every adverse outcome”. It adds: “The office is required by statute to audit a participant’s use of its AI while an agreement remains in effect”.
What the Evaluators Page Says
A second page, on third-party evaluators, says: “Companies testing AI in Utah’s AI Learning Laboratory report on their own performance. This office does not want to rely on those reports alone”. It says the Office “has signed agreements with six independent organizations” that can review a proposal before it is approved and check a pilot’s work while it runs.
The page names the six: Coalition for Health AI, Stanford Clinical Excellence Research Center, Clarion AI Partners, mpathic, Vega Health and Glacis Technologies. Each is a memorandum of understanding, signed between August 10 and October 2, 2026. The page says “These agreements grant no regulatory relief”, and that “The evaluation criteria are being finalized with each organization now”.
On who pays, it says: “The company being evaluated pays the evaluator directly. The state does not pay for evaluations”, and that attestation receipts “are free to the companies required to produce them”.
Under “Runtime Attestation”, the page says: “Companies this office selects must produce a tamper evident digital receipt each time a specified safety check runs. A receipt shows the check ran. It does not show that the AI is safe or that the company followed the law”.
The Structural Read
The August AI entry lists its review as a sequence: the first 250 refills reviewed before they reach the patient, the next 1,000 reviewed afterward, then spot checks of at least 5 percent of refills in every medication class. The page also says each new phase requires the Office’s written approval.
The page pairs the review with limits on each refill. It lists no more than three AI refills in a row for any medication at the start, after which the patient must see a human provider, and identity verification plus a check of the patient’s pharmacy record before any refill. It lists signs that stop a refill and send it to a licensed provider: suicidal thinking, a new side effect, a dangerous interaction or missing lab monitoring.
The page says a demonstration period runs no longer than 12 months and that the Office may end an agreement at any time and for any reason. It also says taking part in the sandbox does not mean the State of Utah has approved, endorsed, certified or vouched for the product.
The Utah Office of AI Policy, Third-Party Evaluators page
“A receipt shows the check ran. It does not show that the AI is safe or that the company followed the law.”
Three Implications
THE TERMS BELONG TO A PILOT THAT HAS NOT STARTED The Office’s page says the demonstration period has not started yet. This publication found no refill counts, review results or adverse events in the two pages it read.
EACH NEW PHASE NEEDS WRITTEN APPROVAL The page says each new phase requires the Office’s written approval, and that after the first 250 refills and the next 1,000, providers spot check at least 5 percent of refills in every medication class.
WHAT THE PAGES LEAVE OPEN The two pages do not say whether the six evaluators or the attestation requirement apply to August AI’s pilot, and the evaluators page says the evaluation criteria are still being finalized. This publication did not read the signed agreement.
What Is Not Established
The pilot has not started. The Office’s page says “The demonstration period has not started yet”, so there are no refill counts, review results or adverse events in what this publication read.
This publication read the Authorized Pilots page and the Third-Party Evaluators page. The Authorized Pilots page says each pilot’s page contains the signed agreement, and this publication did not read it, including Schedule A and the list of medications. It also did not read August AI’s own announcement, and did not contact the Office, August Labs, Inc. or the Division of Professional Licensing.
The two pages do not say whether any of the six evaluators, or the attestation requirement, applies to August AI’s pilot, and this publication does not say that they do. The evaluators page says the evaluation criteria are still being finalized. Nothing here says whether the review ramp is enough, or whether the refills would be safe. This publication’s separate report on the UK government’s response on regulating AI in healthcare is a different document, and nothing here compares the two.
Business Engineer Framework
The Map of AI — Where Each Product Sits in the Stack
The Map of AI places more than 200 companies across nine layers of the stack, from silicon to application, so you can see where the products behind a story sit and what is beneath them.
The Utah Office of Artificial Intelligence Policy’s public record lists August AI’s refill pilot as approved and signed on October 2, 2026, with the demonstration period not yet started. It describes a review that loosens in steps: the first 250 refills reviewed before they reach the patient, the next 1,000 reviewed afterward, then spot checks of at least 5 percent per medication class, each new phase needing the Office’s written approval.
Its separate evaluators page says a tamper-evident receipt “shows the check ran” and does not show that the AI is safe.
A note on sourcing. We drew this piece entirely from the Utah Office of Artificial Intelligence Policy’s Authorized Pilots and Third-Party Evaluators pages, both read on 6 October 2026 at commerce.utah.gov, and we have not checked their contents independently. We did not read the signed agreement and did not contact the Office, August Labs, or the Division of Professional Licensing. Nothing here forecasts outcomes or constitutes medical, legal, or investment advice.
Gennaro is the creator of FourWeekMBA, which reached about four million business people, comprising C-level executives, investors, analysts, product managers, and aspiring digital entrepreneurs in 2022 alone | He is also Director of Sales for a high-tech scaleup in the AI Industry | In 2012, Gennaro earned an International MBA with emphasis on Corporate Finance and Business Strategy.
Scroll to Top
Discover more from FourWeekMBA
Subscribe now to keep reading and get access to the full archive.
